mardi 6 décembre 2016

Onco Actu du 6 décembre 2016

3.1 Tabac

No safe level of smoking: Even low-intensity smokers are at increased risk of earlier death [NIH]

Take a Number: A New Low for Cigarette Smoking [NY Times]

Even with one cigarette a day, odds of early death are higher [Reuters]

3.2 Prévention - Obésité

The sugar tax: a sweet stocking filler? [Cancer Research UK]

UK pushes ahead with sugar tax [BBC News]

3.8 Prévention - Alimentation

Handful of nuts 'cuts heart disease and cancer' risk [NHS Choices]

4.10 Dép., diag. & prono. - Poumon

App launched to help doctors assess risk of lung cancer in people with lung nodules [Cancer Research UK]

5. Traitements

AstraZeneca pill slashes lung cancer progression in study [Reuters]

5.13 WCLC

IASLC WCLC 2016 - Sunday Press Briefing Summary [IASLC]

ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer [Ariad]

ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations [Celgene]

5.2.1 Pharma - Partenariats

AbbVie and Johns Hopkins to Collaborate on Cancer Research [AbbVie]

AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement [AbbVie]

5.3 Traitements - FDA, EMA, NICE...

Key FDA official who fought to uphold agency standards to retire [STAT]

7 ways to make the FDA great again, from a former agency official [STAT]

5.4 Traitements - Economie

Global prescription drug spend seen at $1.5 trillion in 2021: report [Reuters]

5.8 ASH

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting [The Street]

5.8.1 ASH - Communiqués

Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response in Patients with Relapsed or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma [Juno]

Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia [Pfizer]

Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting [Seattle Genetics]

Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting [Seattle Genetics]

Immunotherapy agent yields full and partial remissions in patients with aggressive non-Hodgkin lymphomas, study finds [Dana-Farber]

Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting [BMS]

New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product [Novartis]

KEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology [Merck]

Updated KEYTRUDA® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology [Merck]

Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec® [Novartis]

Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work [Novartis]

New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®) [AbbVie]

5.8.3 ASH - Divers

Mutations in lymphoma patients undergoing transplants raise risk of second cancers [Dana-Farber]

Roche's Gazyva aims to beat blockbuster Rituxan. Can its latest ASH data help? [FierceBiotech]

GALLIUM turns Gazyva into gold in NHL [OBR]

Pfizer's blood cancer drug Bosulif effective in untreated patients [Reuters]

Study raises questions over benefit of Roche's Gazyva cancer drug [Reuters]

5.8.4 ASH - CAR T

Immunotherapy shows promise in preventing leukemia relapse [Fred Hutch]

Can CAR-T cancer treatments be fine-tuned to avoid toxic side effects? [FierceBiotech]

Juno gets some badly needed relief after a glimpse of upbeat early data on JCAR017 [EndPoints]

5.8.5 ASH - Myélome multiple

Early treatment may prevent progression to multiple myeloma [Dana-Farber]

Daratumumab (DARZALEX®) Combination Therapy Showed Consistent Clinical Benefit for Previously-Treated Patients with Multiple Myeloma [Johnson & Johnson]

5.8.6 ASH - Leucémies

Drug combination yields encouraging results in patients with relapsed forms of leukemia or lymphoma in early stage study [Dana-Farber]

Children with Down syndrome and acute lymphoblastic leukemia fare as well as other children treated on Dana-Farber ALL Consortium protocols [Dana-Farber]

A New Antibody For Treating Acute Lymphocytic Leukemia? [Forbes]

6. Lutte contre les cancers

Cancer Moonshot Resource Center [Elsevier]

6.1 Observation

Suicide in Survivors of Cancer in Childhood, Adolescence and Young Adulthood [ESMO]

6.10.1 Politiques (USA)

With Nod To Biden, Senate To Say Yes To “Cures” Spending, Reform Bill [Xconomy]

The 21st Century Cures Act: A Giant Piñata [In the Pipeline]

Winners and losers of the 21st Century Cures Act [STAT]

The 21st Century Cures Act: A huge handout to the drug industry disguised as a pro-research bounty [LA Times]